A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2001
10/18/2001	WO2001077326A1 Novel g protein-coupled receptor protein and dna thereof
10/18/2001	WO2001077325A1 Novel g protein-coupled receptor protein and dna thereof
10/18/2001	WO2001077322A1 Cryptic-like secreted protein
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077170A2 Multiprotein-complexes comprising a nmda receptor and uses thereof
10/18/2001	WO2001077169A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	WO2001077164A2 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077147A2 New bromodomain protein
10/18/2001	WO2001077146A2 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	WO2001077145A2 Integrin binding peptide derivatives
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077136A1 Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
10/18/2001	WO2001077110A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077097A2 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001077095A2 Derivatives of alpha-mercaptoacetamide
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/18/2001	WO2001077089A1 New neurokinin antagonists for use as medicaments
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077079A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001077077A1 Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001077067A2 Solid phase synthesis of lxr ligands
10/18/2001	WO2001077057A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001077055A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076632A1 Formulation for the prevention of cardiovascular disease
10/18/2001	WO2001076616A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	WO2001076584A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	WO2001076574A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
10/18/2001	WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076531A2 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001076451A2 Diagnosis of diseases associated with metabolism
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001038316A3 Sulfonyl oxazole amines and their use as 5-ht6 receptor ligands
10/18/2001	WO2001023388A3 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	US20010032015 In vitro modification of cardiac valvular xenografts
10/18/2001	US20010031882 Lipoxin compounds and their use in treating cell proliferative disorders
10/18/2001	US20010031874 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
10/18/2001	US20010031870 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors
10/18/2001	US20010031857 Memno peptides, process for their preparation and use thereof
10/18/2001	US20010031788 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031770 Pyridoxal analogues and methods of treatment
10/18/2001	US20010031763 Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents
10/18/2001	US20010031758 Administering compounds such as 4-(2-(2-(4-methoxyphenyl) ethylamino)ethyl)amino-2-methyl-9-(2-,4,6-trimethylphenyl)-9h-pyridino(2,3 -b)indole as neuropeptide y receptor antagonists to treat feeding disorders, etc
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031746 Nervous system disorders; psychological disorders
10/18/2001	US20010031744 Using mixture of plant extract and angiogenesis inhibitor
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031730 Method for treatment of glutamate related disorders
10/18/2001	US20010031485 Nucleic acid coding for fusion protein which binds receptor; internalized by endocytosis; inhibits ribosomes and angiogenesis; therapy for tumors, metastasis, eye disorders, chronic inflammation and ischemic injuries
10/18/2001	US20010031474 Chimeric neuropeptide Y receptors
10/18/2001	US20010031282 Dissolving solid in dimethyl ether under pressure; precipitation; separation
10/18/2001	US20010031265 Soaking in solution; then culturing
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405895A1 Combination of organic compounds
10/18/2001	CA2405870A1 Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
10/18/2001	CA2405800A1 Novel secreted protein
10/18/2001	CA2405793A1 Combination of organic compounds
10/18/2001	CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	CA2405561A1 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
10/18/2001	CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	CA2405411A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	CA2405311A1 Multiprotein-complexes comprising a nmda receptor and uses thereof
10/18/2001	CA2405306A1 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	CA2405151A1 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	CA2405104A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405083A1 New bromodomain protein
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404644A1 Modulators of prorenin activity
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2403946A1 Genes expressed in foam cell differentiation
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403263A1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403144A1 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2401290A1 Novel g protein-coupled receptor protein and dna thereof
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1146046A2 Pyropheophorbides and their use in photodynamic therapy
10/17/2001	EP1145718A1 DICARBA-closo-DODECABORANE DERIVATIVES

1 ... 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 ... 1595